Literature DB >> 9853084

[Growth hormone treatment of familial hypophosphatemic rickets].

G Saggese1, G I Baroncelli, S Barsanti.   

Abstract

X-linked hypophosphatemic rickets (XLHR) is frequently associated with growth retardation and short adult stature, even with an appropriate conventional treatment associating phosphate and calcitriol or 1 alpha-hydroxyvitamin D. Its pathogenesis is unclear; growth hormone (GH) secretion is usually normal. Six children with XLHR and growth retardation were treated with GH during 6 years. In addition, they received the conventional treatment. At the beginning of the treatment mean age was 7.8 +/- 1.8 years, and height mean Z score was -3.4 +/- 0.5. A control group was composed of six children with XLHR (age: 7.9 +/- 2.5 years) receiving the conventional treatment only. Under GH treatment statural growth was improved, with significant increase in Z score and predicted adult height; the height gain was significantly higher in the GH treated group as compared with the group receiving the conventional treatment only. In addition, radial bone mineral density increased significantly under GH treatment. GH treatment thus appears to be a useful treatment to improve statural growth in children with XLHR.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9853084     DOI: 10.1016/s0929-693x(99)80191-2

Source DB:  PubMed          Journal:  Arch Pediatr        ISSN: 0929-693X            Impact factor:   1.180


  3 in total

Review 1.  Recombinant growth hormone therapy for X-linked hypophosphatemia in children.

Authors:  Sherie Smith; Tracey Remmington
Journal:  Cochrane Database Syst Rev       Date:  2021-10-07

Review 2.  Emerging options in growth hormone therapy: an update.

Authors:  Stephen F Kemp; J Paul Frindik
Journal:  Drug Des Devel Ther       Date:  2011-08-30       Impact factor: 4.162

3.  X-linked vitamin D-resistant rickets: 12 years of follow-up.

Authors:  Ahmed Anas Guerboub; Souad Moussaoui; Jad Issouani; Yassine Errahali; Ghizlaine Belmejdoub
Journal:  Pan Afr Med J       Date:  2018-05-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.